New mass spectrometric assay for angiotensin-converting enzyme 2 activity

Khalid M. Elased, Tatiana S. Cunha, Susan Gurley, Thomas M. Coffman, Mariana Morris

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

A novel assay was developed for evaluation of mouse angiotensin-converting enzyme (ACE) 2 and recombinant human ACE2 (rACE2) activity. Using surface-enhanced laser desorption/ionization time of flight mass spectrometry (MS) with ProteinChip Array technology, ACE1 and ACE2 activity could be measured using natural peptide substrates. Plasma from C57BL/6 mice, kidney from wild-type and ACE2 knockout mice, and rACE2 were used for assay validation. Plasma or tissue extracts were incubated with angiotensin I (Ang I; 1296 m/z) or angiotensin II (Ang II; 1045 m/z). Reaction mixtures were spotted onto the ProteinChips WCX2 and peptides detected using surface-enhanced laser desorption/ionization time of flight MS. MS peaks for the substrates, Ang I and Ang II, and the generated peptides, Ang (1-7) and Ang (1-9), were monitored. The ACE2 inhibitor MLN 4760 (0.01 to 100 μmol/L) significantly inhibited rACE2 activity (IC50=3 nmol/L). Ang II was preferably cleaved by rACE2 (km=5 μmol/L), whereas Ang I was not a good substrate for rACE2. There was no detectable ACE2 activity in plasma. Assay specificity was validated in a model of ACE2 gene deletion. In kidney extract from ACE2-deficient mice, there was no generation of Ang (1-7) from Ang II. However, Ang (1-7) was produced when Ang I was used as a substrate. In conclusion, we developed a specific and sensitive assay for ACE2 activity, which used the natural endogenous peptide substrate Ang II. This approach allows for the rapid screening for ACE2, which has applications in drug testing, high-throughput enzymatic assays, and identification of novel substrates/inhibitors of the renin-angiotensin system.

Original languageEnglish (US)
Pages (from-to)1010-1017
Number of pages8
JournalHypertension
Volume47
Issue number5
DOIs
StatePublished - May 1 2006
Externally publishedYes

Fingerprint

Mass Spectrometry
Protein Array Analysis
Peptides
Human Activities
Lasers
Kidney
Angiotensin I
Tissue Extracts
Gene Deletion
Enzyme Assays
Renin-Angiotensin System
Inbred C57BL Mouse
Knockout Mice
Angiotensin II
Inhibitory Concentration 50
Technology
angiotensin converting enzyme 2
Pharmaceutical Preparations
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid
angiotensin I (1-9)

Keywords

  • Angiotensin
  • Angiotensin converting enzyme
  • Mice
  • Renin-angiotensin system

ASJC Scopus subject areas

  • Internal Medicine

Cite this

New mass spectrometric assay for angiotensin-converting enzyme 2 activity. / Elased, Khalid M.; Cunha, Tatiana S.; Gurley, Susan; Coffman, Thomas M.; Morris, Mariana.

In: Hypertension, Vol. 47, No. 5, 01.05.2006, p. 1010-1017.

Research output: Contribution to journalArticle

Elased, Khalid M. ; Cunha, Tatiana S. ; Gurley, Susan ; Coffman, Thomas M. ; Morris, Mariana. / New mass spectrometric assay for angiotensin-converting enzyme 2 activity. In: Hypertension. 2006 ; Vol. 47, No. 5. pp. 1010-1017.
@article{296757e2464840a18d2e101e6ca7be4b,
title = "New mass spectrometric assay for angiotensin-converting enzyme 2 activity",
abstract = "A novel assay was developed for evaluation of mouse angiotensin-converting enzyme (ACE) 2 and recombinant human ACE2 (rACE2) activity. Using surface-enhanced laser desorption/ionization time of flight mass spectrometry (MS) with ProteinChip Array technology, ACE1 and ACE2 activity could be measured using natural peptide substrates. Plasma from C57BL/6 mice, kidney from wild-type and ACE2 knockout mice, and rACE2 were used for assay validation. Plasma or tissue extracts were incubated with angiotensin I (Ang I; 1296 m/z) or angiotensin II (Ang II; 1045 m/z). Reaction mixtures were spotted onto the ProteinChips WCX2 and peptides detected using surface-enhanced laser desorption/ionization time of flight MS. MS peaks for the substrates, Ang I and Ang II, and the generated peptides, Ang (1-7) and Ang (1-9), were monitored. The ACE2 inhibitor MLN 4760 (0.01 to 100 μmol/L) significantly inhibited rACE2 activity (IC50=3 nmol/L). Ang II was preferably cleaved by rACE2 (km=5 μmol/L), whereas Ang I was not a good substrate for rACE2. There was no detectable ACE2 activity in plasma. Assay specificity was validated in a model of ACE2 gene deletion. In kidney extract from ACE2-deficient mice, there was no generation of Ang (1-7) from Ang II. However, Ang (1-7) was produced when Ang I was used as a substrate. In conclusion, we developed a specific and sensitive assay for ACE2 activity, which used the natural endogenous peptide substrate Ang II. This approach allows for the rapid screening for ACE2, which has applications in drug testing, high-throughput enzymatic assays, and identification of novel substrates/inhibitors of the renin-angiotensin system.",
keywords = "Angiotensin, Angiotensin converting enzyme, Mice, Renin-angiotensin system",
author = "Elased, {Khalid M.} and Cunha, {Tatiana S.} and Susan Gurley and Coffman, {Thomas M.} and Mariana Morris",
year = "2006",
month = "5",
day = "1",
doi = "10.1161/01.HYP.0000215588.38536.30",
language = "English (US)",
volume = "47",
pages = "1010--1017",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - New mass spectrometric assay for angiotensin-converting enzyme 2 activity

AU - Elased, Khalid M.

AU - Cunha, Tatiana S.

AU - Gurley, Susan

AU - Coffman, Thomas M.

AU - Morris, Mariana

PY - 2006/5/1

Y1 - 2006/5/1

N2 - A novel assay was developed for evaluation of mouse angiotensin-converting enzyme (ACE) 2 and recombinant human ACE2 (rACE2) activity. Using surface-enhanced laser desorption/ionization time of flight mass spectrometry (MS) with ProteinChip Array technology, ACE1 and ACE2 activity could be measured using natural peptide substrates. Plasma from C57BL/6 mice, kidney from wild-type and ACE2 knockout mice, and rACE2 were used for assay validation. Plasma or tissue extracts were incubated with angiotensin I (Ang I; 1296 m/z) or angiotensin II (Ang II; 1045 m/z). Reaction mixtures were spotted onto the ProteinChips WCX2 and peptides detected using surface-enhanced laser desorption/ionization time of flight MS. MS peaks for the substrates, Ang I and Ang II, and the generated peptides, Ang (1-7) and Ang (1-9), were monitored. The ACE2 inhibitor MLN 4760 (0.01 to 100 μmol/L) significantly inhibited rACE2 activity (IC50=3 nmol/L). Ang II was preferably cleaved by rACE2 (km=5 μmol/L), whereas Ang I was not a good substrate for rACE2. There was no detectable ACE2 activity in plasma. Assay specificity was validated in a model of ACE2 gene deletion. In kidney extract from ACE2-deficient mice, there was no generation of Ang (1-7) from Ang II. However, Ang (1-7) was produced when Ang I was used as a substrate. In conclusion, we developed a specific and sensitive assay for ACE2 activity, which used the natural endogenous peptide substrate Ang II. This approach allows for the rapid screening for ACE2, which has applications in drug testing, high-throughput enzymatic assays, and identification of novel substrates/inhibitors of the renin-angiotensin system.

AB - A novel assay was developed for evaluation of mouse angiotensin-converting enzyme (ACE) 2 and recombinant human ACE2 (rACE2) activity. Using surface-enhanced laser desorption/ionization time of flight mass spectrometry (MS) with ProteinChip Array technology, ACE1 and ACE2 activity could be measured using natural peptide substrates. Plasma from C57BL/6 mice, kidney from wild-type and ACE2 knockout mice, and rACE2 were used for assay validation. Plasma or tissue extracts were incubated with angiotensin I (Ang I; 1296 m/z) or angiotensin II (Ang II; 1045 m/z). Reaction mixtures were spotted onto the ProteinChips WCX2 and peptides detected using surface-enhanced laser desorption/ionization time of flight MS. MS peaks for the substrates, Ang I and Ang II, and the generated peptides, Ang (1-7) and Ang (1-9), were monitored. The ACE2 inhibitor MLN 4760 (0.01 to 100 μmol/L) significantly inhibited rACE2 activity (IC50=3 nmol/L). Ang II was preferably cleaved by rACE2 (km=5 μmol/L), whereas Ang I was not a good substrate for rACE2. There was no detectable ACE2 activity in plasma. Assay specificity was validated in a model of ACE2 gene deletion. In kidney extract from ACE2-deficient mice, there was no generation of Ang (1-7) from Ang II. However, Ang (1-7) was produced when Ang I was used as a substrate. In conclusion, we developed a specific and sensitive assay for ACE2 activity, which used the natural endogenous peptide substrate Ang II. This approach allows for the rapid screening for ACE2, which has applications in drug testing, high-throughput enzymatic assays, and identification of novel substrates/inhibitors of the renin-angiotensin system.

KW - Angiotensin

KW - Angiotensin converting enzyme

KW - Mice

KW - Renin-angiotensin system

UR - http://www.scopus.com/inward/record.url?scp=33646145519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646145519&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.0000215588.38536.30

DO - 10.1161/01.HYP.0000215588.38536.30

M3 - Article

VL - 47

SP - 1010

EP - 1017

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 5

ER -